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Summary
Allogeneic bone marrow transplantation (BMT) has been associated with a graft-vs.-leukemia
(GVL) reactivity. Since T cell depletion of the bonemarrow graft has decreased the risk of graft-
vs.-host disease (GVHD), but has been associated with higher rates of leukemia relapse, GVL
reactivity is probably caused by donor-derived T lymphocytes. Previously, we demonstrated that
minor histocompatibility (mH) antigen-specific cytotoxic T lymphocyte (CTL) clones, gener-
ated from patients afterBMT, are capable of major histocompatibilitycomplex-(MHC) restricted
lysis of (clonogenic) myeloid leukemic cells. Here, we investigated whether donor-derived leukemia-
specific CTL clones can be generated in vitro, before BMT, using irradiated leukemic cells from
a patient with acute myeloid leukemia as stimulator cells, and peripheral blood or bone marrow
from the HLA genotypically identical sibling donor as responder cells . Several CTL lines were
generated that showed specific lysis (>50%) of the recipient leukemic cells in a "Cr-release assay.
Two of these CTL lines were cloned by limiting dilution in the presence of the irradiated recip-
ient cells. Multiple leukemia-reactive, HLA class I and II-restricted clones with various specificities
could be established . These alloreactive, antileukemic CTL clones may cause GVL reactivity after
BMT, and may be used as adjuvant immunotherapy in the treatment of leukemia .
Alogenic bone marrow transplantation (BMT)t has been
associated with a graft-vs.-leukemia (GVL) reactivity
(1-4) . ThisGVL reactivity is probably caused by donor-derived
T lymphocytes from the graft since T lymphocyte depletion
of the bonemarrow graft is correlated with an increased risk
ofleukemic relapse after BMT, and an inverse correlation has
been found between the occurrence ofGVHD and relapse
ofleukemia in HLAidenticalBMT (5-7) . Alloantigen-specific
CTLs may be responsible for the GVL reactivity, since this
GVL effect has not been observed in transplants between
homozygous twins.
Minor histocompatibility (mH) antigens appear to play
a major role in the etiology ofGVHD, graft rejection, and
GVL reactivity afterBMT between HLA genotypically iden-
tical siblings, and MHC-restricted mH antigen-specificCTL
lines can be isolated after HLA-identical BMT from patients
with GVHD or graft rejection (8-13) . We recently demon-
strated thatmH antigen-specific CTL lines can be generated
in vitro, without in vivo priming, by stimulation with HLA-
1 Abbreviations used in this paper: AML, acute myeloid leukemia ; BMT,
bone marrow transplantation ; CML, chronic myeloid leukemia; GVL, graft-
vs .-leukemia ; LCL, lymphoblastoid cell line ; mH, minor histocompati-
bility; MNC, mononuclear cells; TCGF, T cell growth factor.
identical bone marrow cells, and that mH antigen-specific
CTL clones are capable of antigen-specific MHC-restricted
lysis of (clonogenic) normal and leukemic precursor cells
(14-16) . Here, we have investigated whether it is possible
to generate leukemia-specific CTL clones from the HLA geno-
typically identical sibling donor of a patient with acute my-
eloid leukemia (AML) .
Materials and Methods
Generation ofLeukemia-specificCTL Clones.
￿
After informed con-
sent, bone marrow and peripheral blood from a patient withAML
and from her HLA-identical sibling donor were obtained . The
patient was a 29-yr-old female with AML, subtype M5 according
to theFAB classification, and cytogenetic analysis revealed a trans-
location t(8;16)(pll;pl3) . Complete remission was achieved af-
ter treatment with Daunorubicin and arabinosyl-cytosine (ARA-C) .
After a consolidation course with high doseARA-C and amsacrin
(Amsa), allogeneic BMT with the bone marrow from her HLA
genotypically identical sister was performed . HLA typing was per-
formed by standard serological methods . The HLA typing of the
family was as follows : father A2 B7 Cw7 DR15(2) DQ6/A2 B27
CW1 DRl DQ5 ; mother Al B8 CW7DR3 DQ2/A24 B8 CW7
DR3 DQ2 ; sib 1 (patient) A2 B7 CW7 DR15(2) DQ6/A24 B8
CW7 DR3 DQ2 ; and sib 2 (donor)A2 B7 CW7 DR15(2)DQ6/
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gosity of a complete haplotype of the parents of the patient and
herHLA identical sibling, which illustrates that the patient and
herdonor are not only phenotypically, but also genotypicallyHLA
identical . Pretransplant primaryMLRand cell-mediated lysis assays
between donor and patient were negative .
2 x 106 irradiated (30 Gy) leukemic bone marrow or periph-
eral blood mononuclear cells (MNC) (>95% morphologically
recognizable leukemic cells) from the patient were used as stimu-
lator cells, and 106bone marrow or peripheral blood (MNC) from
her HLA genotypically identical sibling donor, were used as re-
sponder cells . The cells were cultured in 50-ml flasks in medium
consisting ofRPMI plus 15% prescreened human AB serum. On
day 6, 20%T cell growth factor (TCGF; Biotest, Offenbach, Ger-
many) was added to the medium, and on day 9 the cells were res-
timulated with 10-fold of the irradiated leukemic cells from the
recipient . Between days 16 and 20 the generated CTL lines were
tested in a "Cr-release assay. Two of the CTL lines that showed
specific reactivity (specific lysis >50%) with the recipient leukemic
cells were further cloned by limiting dilution (effector cell concen-
tration 1 :0.3 cell/well) in the presence of the irradiated recipient
leukemic cells (30 Gy) and in the presence of 20% TCGF . The
generated CTL clones were further expanded in the presence of
the irradiated (30Gy) leukemic cells from the recipient in the pres-
ence of irradiated (30 Gy) allogeneic peripheral blood MNC.
In the same way, CTL lines were generated after BMT using
106 peripheral bloodMNC from the recipient, collected 6 mo after
BMT, as responder cells, and 2 x 10 6 irradiated (30Gy) recipient
leukemic bone marrow cells as stimulator cells .
The phenotypes oftheCTLclones were analyzed on aFACScan®
(all from Becton Dickinson & Co ., Mountain View, CA) using
CD3, CD4, and CD8 mAbs .
Target Cells .
￿
Lymphocytes were expanded by stimulating 10'
peripheral bloodMNC from the patient or donor or from various
HLA genotypically identical sibling pairswith 0.2% PHA (Difco
Laboratories, Detroit, MI) in RPMI plus 15% human AB serum
for 3 d . The cells were then washed and further cultured in the
absence ofPHA in the presence of human recombinant IL-2 300
IU/ml, for at least three more days .
Stable EBVtransformed B cells (EBVlymphoblastoid cell lines
[LCLs]) were established by in vitro transformation of 10' periph-
eral bloodMNC with EBV supernatant for 1.5 h . The cells were
washed and further cultured in RPMI plus 10% FCS (Gibco Labora-
tories, Grand Island, NY).
Samples ofleukemic cells from patients with AML or chronic
myeloid leukemia (CML) were obtained, after informed consent,
from the peripheral blood or bone marrow of the patients before
treatment . Patients with >95% morphologically recognizable leu-
kemic cells in their peripheral blood or bone marrow were selected.
The cells were centrifuged over Ficoll Isopaque (density 1.077
g/cm 3 , 1,000 g, 20 min) and the interphase cells were harvested.
For cryopreservation, the cells were resuspended in medium con-
sisting of 65% RPMI, 25% FCS, and 10% DMSO, frozen, and
preserved in liquid nitrogen. Before use, the cells were thawed,
washed twice, and resuspended in RPMI containing 15%
prescreened AB serum .
"Cr-release Assay.
￿
Standard 5'Cr-release assays were performed
as described (17) . Briefly, target cells consisting of lymphocyte popu-
lations, leukemic cells, or EBVLCLs were labeled with 0.1 ml
Na 5'CrO4 (100 /ACi) for 1 h at 37°C, washed three times, and
resuspended in RPMI plus 15% AB serum at a concentration of
5 x 10 4 viable cells/ml . 0.1 ml of the effector population and 0.1
ml of the target suspension were added to each well of a round-
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bottomed microtiter plate at anE/T ratio rangingfrom 5:1 to 1:1 .
Target and effector cells were incubated for 4 h at 37°C. To mea-
sure spontaneous release of 5'Cr, 0.1 ml of the target suspension
was added to 0.1 ml RPMI plus 15% AB serum without effector
cells. Maximum release was determined by adding 0.1 ml of the
target suspension to 0.1 ml zaponine solution .
The percent specific lysis obtained in a "Cr-release assay was
determined as follows : 100 x [(experimental releasecpm - spon-
taneous release cpm)/(maximum release cpm - spontaneous re-
lease cpm)] .
To determine CD4 and class II or CD8 and class I restriction
of the recognition of the target cells, blocking studies were per-
formed. Effector cells were incubated with saturated concentra-
tions of anti-CD4 or anti-CD8 mAbs (RIV6 and FK18, respec-
tively, [18, 19]) or target cells with anti-class I or anti-class IImAbs
(W6/32 and PdV5 .2, respectively [20, 21]) at a final dilution of
1:100 for 30 min before the effector and target cells were cocultured .
To determine whether the antigen, recognized by oneCTLclone
andpresentedby different targets, was similar, a cold target inhibi-
tion assay was performed . Non-"Cr-labeled (cold) target cells were
added to a specific combination of effector cells and 5'Cr-labeled
(hot) target cells (E/T ratio 5 :1) . The cold/hot target ratios used
were 100:1, 30:1, 10:1, and 3 :1 .
The percent inhibition oflysis of hot targetsby cold targets was
measured as follows : 100 x [(% lysis of hot targets only - %
lysis of hot targets with presence of cold targets)/(% lysis of hot
targets only)] .
Results
Several donor-derived CTL lines were generated, that
showed specific lysis (specific lysis >50%) of the recipient
leukemic cells in a "Cr-release assay. Two of these CTL lines
were cloned by limiting dilution in the presence of the ir-
radiated leukemic cells from the recipient and 70 clones could
be isolated, of which 13 showed specific reactivity (specific
lysis >50%) with the leukemic cells from the recipient. Of
these 13 clones, three types of clones could be recognized,
Table 1 .
￿
Specific Recognition by the Three Types of
Donor-derived CTL Clones, Generated against the Leukemic Cells
from the HLA Genotypically Identical Recipient
Generation of Leukemia-reactive Cytotoxic T Lymphocyte Clones
Lysis of the target cells was measured using a standard -"Cr-release as-
say in duplicate at E/T ratio 5:1 .
+ + specific lysis >50% .
- specific lysis <20% .
Spontaneous release cpm/maximum release cpm ratio <25% .
Specific lysis
I II III
Target cells (clone H) (clone Y) (clone S)
Lymphocyte recipients + + - -
Lymphocyte donor - - -
AML recipient + + + + + +
EBV-LCL recipient + + - + +
EBV-LCL donor - - + +TARGET CELLS
EBV-LCL RECIPIENT
- anti-CD8
- anti-Class I
- anti-CD4
- anti-Class II
10 20 30 40 50 60 70 60
PERCENTAGE SPECIFIC LYSIS
Figure 1 .
￿
Blocking studies of clone H, an example of a type I clone,
CD8 positive, that recognized the recipient lymphocytes, leukemic cells,
and EBVLCL. To determine class I restriction of the recognition of the
target cells by clone H, blocking studies were performed . The specific lysis
of the targets was measured using a standard 51Cr-release assay in dupli-
cate at an E/T ratio of 5 :1 . The specific lysis of the recipient EBVLCL
was blocked with anti-CD8 and anti-class I mAbs. Spontaneous release
cpm/maximum cpm ratio <25% .
based on their specific reactivity in a 51Cr-release assay (Table
1) . Type I clone (n = 2) was phenotypically CD8 positive
and showed specific reactivity with the recipient lymphocytes,
leukemic cells, and EBVLCL . Type II clone (n = 2), also
CD8 positive, only showed reactivity with the recipient leu-
kemic cells . Type III clone (n = 9), CD4 positive, recog-
Table 2 .
￿
Specificity of Clone H, An Example of a Type I
Clone, CD8 Positive, that Recognized the Recipient
Lymphocytes, Leukemic Cells, and EBV-LCL
Lysis of lymphocytes from unreleated HLA-identical sibling pairs shar-
ing one or more HLA antigens with the recipient and donor, was mea-
sured using a standard 51Cr-release assay in duplicate at E/T ratio 5 :1 .
HLA recipient/donor : A2 A24 B7 B8 Cw7 DR3 DR15(2) DQ2 DQ6 .
+ + specific lysis >50% .
- specific lysis <20% .
Spontaneous release cpm/maximum release cpm ratio <25% .
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Table 3 .
￿
Specificity of Clone Y, An Example ofa Type II Clone,
CD8 Positive, that Only Recognized the Recipient Leukemic Cells
Lysis of leukemic cells from 21 unrelated patients with AML, sharing
one or more HLA antigens with the recipient and donor, was measured
in a standard 51Cr-release assay in duplicate at E/T ratio 5 :1 . HLA
recipient/donor : A2 A24 B7 B8 Cw7 DR3 DR15(2) DQ2 DQ6 .
+ + specific lysis >50% .
- specific lysis <20% .
Spontaneous release cpm/maximum release cpm ratio <25% .
nized the recipient leukemic cells and EBVLCL from both
recipient and donor. One example of each type of clone was
further characterized.
CloneH is an example of a type I CD8 positive "recipient-
specific" clone, reacting withT lymphocytes, EBVtransformed
B cells (EBVLCL), as well as with the leukemic cells from
the recipient . The specific lysis of the target cells from the
PERCENTAGE SPECIFIC LYSIS
AML RECIPIENT
￿
K562
￿
MOLT 4
￿
DAUDI
￿
HL-60
TARGET CELLS
Figure 2 .
￿
Specificity of clone Y, an example of a type II clone, CD8
positive, that only recognized the recipient leukemic cells. To determine
the possibility of non-MHC-restricted lysis by clone Y the lysis ofseveral
NK or lymphokine-activated killer cell reactive targets was measured using
a standard 51Cr-release assay in duplicate at an E/T ratio of 5 :1. Clone
Y exhibited noMHC nonspecific activity. Spontaneous release cpm/max-
imum release cpm ratio <25% .
HLA antigens shared
with the donor
No .
of pairs
AML
Fab classification
Specific
lysis
A2 1 M5 + +
A2 5 M2/M5 -
A24 1 M5 -
M2A24 1 M5 -
A2B7C7 1 M5 -
A2B8C7 1 M5 -
A24B8C7 2 M5 -
B7C7 1 M3 + +
B7C7 2 M5 -
B8C7 2 M5 -
B7B8 2 M5 -
None 2 M1/M5 -
HLA antigens shared
with the donor No . of pairs
Specific lysis
Sibling 1 Sibling 2
A2C7 1 - -
A2137138127 1 + + + +
A2B8C7 1 - -
A2B7C7 1 + + + +
A2B7C7 1 + + -
A2B7C7 2 - -
A2 3 - -
C7 1 - -
B7C7 1 + + + +
A2A24 2 - -
None 2 - -120
100
A
￿
B
￿
Figure 3 .
￿
Blocking studies of clone Y,
an example of a type II clone, CD8 posi-
tive, that only recognized the recipient
leukemic cells. To determine class I restric-
tion of the recognition ofthe target cells
by clone Y, blocking studies were per-
formed . The specific lysis ofall three leu-
kemic targets, recognizedby cloneY, was
blocked with anti-CD8 and anti-class I
mAbs in a standard 5 1Cr-release assay
(A) . To determine whether the antigen,
0
￿
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￿
40
￿
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￿
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￿
100
￿
0
￿
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￿
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￿
30
￿
80
￿
100
￿
120
￿
three different targets, was similar, a cold
Percentage specific Iysls
￿
COLD TARGET/ HOT TARGET RATIO
target inhibition assay was performed .
Non-5'Cr-labeled (cold) target cells were
D
￿
added to a specific combination ofeffector
cells and 51Cr-labeled (hot) target cells
(E/T ratio 5 :1) . The cold targets were the
leukemic cells of the recipient (O), the
two AML samples recognized by clone
Y (sharing HLA-B7 (+) or HLA-A2 (')
with the recipient) and an AML sample
not recognized by clone Y (sharing the
HLA-A24 (0) with the recipient) . As hot
targets, the three leukemic samples, rec-
ognized by clone Y, were also used : the
recipient leukemic cells (B), the AML
sample sharing the HLA-B7 with the re-
cipient (C), and theAML sample sharing
theHLA-A2with the recipient (D) . The
cold/hot target ratios used were 100 :1, 30 :1, 10 :1, and 3 :1 . When the three targets, recognized by clone Y, were used as cold targets, the specific
lysis of the hot target, the recipient leukemic cells, could be inhibited by two of the cold targets, the cold target AML-A2 (') was not clearly inhibitory
(B) . When the AML-B7 or the AML-A2 was used as hot target, all three specific cold targets could inhibit the specific lysis of these two hot targets
(C, D) . In all three assays, the cold target AML-A24 (0) could not significantly inhibit the specific lysis of the hot targets (B-D) . Spontaneous release
cpm/maximum release cpm <25% .
Target cells
AML RECIPIENT IMS)
.nscLASS 1
anal-CDs
AML-A2 (1,15)
anti-CLASS 1
. anti-CD8
AML-117C7 (M3)
anti-CLASS 1
anti-CDS
HOT TARGET : AML-B7
PERCENTAGE INHIBITION OF LYSIS
C
20 40 80 so 100 120
COLD TARGET/ HOT TARGET RATIO
HOTTARGET : LEUK-R
PERCENTAGE INHIBITION OF LYSIS
100,
so
80
40-
20-
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100
recipient by clone H could be blocked with CD8 and anti-
class I mAbs illustrating class I-restricted recognition (Fig .
1) . Clone H was tested in a "Cr-release assay against a panel
of lymphocytes from unrelated HLA identical sibling pairs
sharing one or more HLA antigens with the recipient and
donor (Table 2) . Only target cells expressing HLA-137 an-
tigens were lysed by clone H . Possible reactivity against a
subtype of HLA-137 could be excluded, since donor and re-
cipient were genotypically identical, and the HLA-137 locus
was present only once in the parental haplotypes. Further-
more, not all target cells expressing the HLA-B7 antigens
were lysed by clone H . Differential recognition of the lym-
phocytes of one of the unrelated genotypically identical sib-
ling pairs expressing the HLAB7 antigen illustrated that clone
H was directed against amH antigen, and that the recogni-
tion was HLA-137 restricted.
Clone Y, an example of the type II clone, CD8 positive,
which only recognized the recipient leukemic cells, was tested
in a "Cr-release assay against a panel of leukemic cells from
21 patients with AML, Fab classification M2, M3, or M5
(Table 3) . Two AML targets sharing no HLA antigens with
the recipient and donor were not lysed by clone Y Of six
targets sharing HLA-A2 with the recipient and donor, one
was recognized by cloneY Of 13 other targets sharing cer-
tainHLA antigens with the recipient and the donor in different
combinations, oneAML target sharing HLAB7C7 with the
recipient and donor was lysed by this CTL clone . Clone Y
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exhibited noMHC nonspecific activity as demonstrated by
the lack of reactivity with K562, Molt 4, Daudi, and HL60
cells in a 51Cr-release assay (Fig . 2) . In contrast, the specific
lysis of these targets could be inhibited with anti-CD8 and
anti-class I mAbs (Fig . 3A) . No blocking was observed with
anti-CD4 and anti-class II mAbs .
Target cells
-a
AML RECIPIENT
+ anti-CD4
+ anti-CLASS II
+ anti-CD8
+ anti-CLASS I
EBV-LCL RECIPIENT
+ anti-CD4
+ anti-CLASS II
+ anti-CD8
+ anti-CLASS I
Figure 4 .
￿
Specificity of clone S, an example of a type III clone, CD4
positive, that showed specificlysis ofthe recipient leukemic cells andEBV
LCL from both recipient and donor. To determine class II restriction of
the recognition of the target cells by clone S blocking studies were per-
formed . The specific lysis of the targets was measured using a 5'Cr-release
assay in duplicate at an E/T ratio of5 :1. The specific lysis of the recipient
leukemic cells and EBVLCL was blocked with anti-CD4 and anti-class
II mAbs. Spontaneous release cpm/maximum release cpm <25% .
Generation of Leukemia-reactive Cytotoxic T Lymphocyte Clones
_ - recognized by cloneY and presented by
0 20 40 60 so 100 120
Percentage specific lysisWhen the targets, recognized by clone Y, were used as
competitors in a cold target inhibition assay, the specific lysis
of the hot target, the recipient leukemic cells, could be in-
hibited by both cold targets, the recipient leukemic cells (O)
and the AML-137 (+) (Fig . 3 B) . The cold target AML-A2
(") was not clearly inhibitory (Fig . 3 B). The specific recog-
nition of the AML-A2 leukemic sample was lower than that
of the AML-137 leukemic sample (Fig. 3A) . When theAML
B7 target was used as hot target, the cold targets, the recip-
ient leukemic cells, the AML-137, and the AML-A2 could
strongly inhibit the specific lysis (Fig . 3 C) . The specific lysis
of hot target AML-A2 could also be inhibited by all three
specific cold targets, the recipient leukemic cells, theAML
B7, and the AML-A2 (Fig . 3 D) . In all three assays, the cold
target AML-A24 (p), the target that was not recognized by
clone Y, could not significantly inhibit the specific lysis of
the hot targets (Fig . 3, B, C, and D) .
Clone S, an example of the type III clone, CD4 positive,
showed specific lysis ofthe recipient leukemic cells and EBV
LCL from both recipient and donor (Table 1) . The lysis by
clone S of the recipient leukemic cells and EBVLCL could
be blocked with anti-CD4 and anti-class II mAbs, illustrating
the class II-restricted lysis (Fig. 4) . No blocking was observed
after incubating ofeffector or target cells with anti-CD8 and
anti-class I mAbs. To analyze the possible restriction element,
clone S was tested against a panel of EBVLCLs, homozy-
gous for the various HLA-class II antigens . The specific lysis
by clone S was shown to be HLA-DR2-restricted, and not
restricted by HLA-DP or HLA-DQ (Fig. 5) . Clone S also
recognized other EBVLCLs, heterozygous for the HLA-DR2
antigen (data not shown) . The antigen recognized by clone
S was not specific for an EBVassociated antigen because the
recipient leukemic cells were shown not to be infected by
EBV as measured byPCR or in situ hybridization (22) . Fur-
Figure 5 .
￿
Specificity of clone S, an example of a type III clone, CD4
positive, that showed specific lysis of the recipient leukemic cells andEBV
LCL from both recipient and donor. To analyze the possible restriction
element, clone S was tested against a panel of EBVLCLs, homozygous
for the various HLA- class II antigens . The lysis of the target cells was
measured using a standard s1Cr-release assay in duplicate at an E/T ratio
of 5 :1. The specific Lyis by clone S was shown to beHLA-DR2 restricted.
When clone S was tested against other target cells, expressing the HLA-
DR2 restricting element, only one other AML sample was recognized
by clone S . Spontaneous release cpm/maximum release cpm <25% .
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thermore, DOHH2, an immunoblastic lymphoma cell line,
EBV and HLA-DR2 positive, was not lysed by clone S. The
antigen was further recognized on one other AML sample,
expressing the HLA-DR2 restricting element . Two CML
samples, HLA-DR2 positive, were not recognized by clone
S (Fig. 5) .
The patient described was transplanted with the bone
marrow from herHLA genotypically identical sister . She de-
veloped clinical stage I acute GVHD of the skin 30 d after
BMT, which disappeared after treatment with prednisone.
She is now 24 mo after BMT and in good health . AfterBMT
ofthis patient with her HLA identical donor sibling, leukemia-
reactive CTL lines could also be generated from the recip-
ient, using the peripheral blood MNC from the recipient,
collected 6 mo after BMT, as responder cells, and the irradi-
ated original leukemic bone marrow cells from the recipient
as stimulator cells (Fig. 6) . It was not possible to expand these
generated CTL lines for further analysis of their specificity .
Discussion
Alloreactive, antileukemicCTL clones could be generated
in vitro from the HLA genotypically identical sibling donor
of a patient with AML, using the irradiated leukemic cells
from the recipient as stimulator cells and the bone marrow
or peripheral bloodMNC from the donor, collected before
BMT, as responder cells . Of the 13 cytotoxic clones, which
could be generated in vitro, three types of clones could be
recognized . The specific recognition of the target cellsby clone
H, an example of a CD8 positive recipient-specific clone, ap-
peared to be restricted by HLA-B7 expression . Differential
recognition of lymphocytes from HLA genotypically iden-
tical pairs revealed that this CTL clone exhibited a HLA-
B7-restricted mH antigen-specific recognition . Previously,
it has been described that antihost mH antigen-specific reac-
tivity can be found after HLA-identical BMT not only in
patients with GVHD, but also in patients without clinical
signs of GVHD, or after resolution of acute GVHD (23) .
Clone Y, an example of a CD8 leukemia-specific clone,
Figure 6 .
￿
Specificity of a C138-positive CTL line, generated from the
recipient 6 mo after BMT, against the leukemic cells from the recipient
herself . Lysis of the target cells was measured using a standard "Cr-release
assay in duplicate at an E/T ratio of5 :1. Only the recipient leukemic cells
were recognized by the CTL line. Spontaneous release cpm/maximum
cpm ratio <25%.only showed reactivity with leukemic samples from two other
patients with AML. Because these two samples shared different
HLA antigens with the recipient and donor, the possibility
of non-MHC-restricted lysis by clone Y was analyzed using
several NK or lymphokine-activated killer cell reactive targets.
Since clone Y showed no reactivitywith K562, Molt 4, Daudi,
and HL60 cells in a "Cr-release assay, nonspecific lysis due
to NK activity was excluded. Furthermore, blocking studies
showed that the specific lysis by clone Y of the recipient leu-
kemic cells, but also of the other two AML samples, could
be inhibited with anti-CD8 and anti-class I mAbs, illustrating
HLA-class I-restricted recognition. Cold target inhibition
assays indicated that the antigen recognized by clone Y was
similar on all the three leukemic examples. These results sug-
gest that different MHC determinants may similarly present
the same antigen. Previously, it has been described that one
T lymphocyte clone can recognize an antigen presented by
different restricting HLA-class I antigens (24) . Our results
indicate that clone Y may recognize an antigen that is not
the specific product of the described t(8;16) translocation,
since the two other AML samples did not exhibit this specific
translocation.
Clone S, an example of a C134-positive clone, recognized
EBVLCLs expressing the HLA-DR2 antigen, which sug-
gests that the antigen recognized by clone S was EBV as-
sociated. However, using the PCR with EBVspecific primers
and in situ hybridization, EBV infection of the leukemic cells
of the recipient could not be demonstrated. Furthermore, a
human immunoblastic B cell line (DOHH2), EBV and HLA
DR2 positive, was not recognized by clone S. The antigen
recognized by clone S and restricted by HLA-DR2 expres-
sion, was also presented by one other AML (M5) sample,
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but not by two HLADR2 positive chronic myeloid leukemic
samples. To exclude the possibility of nonspecific recogni-
tion of a protein from the human serum or culture medium
used, the assays were repeated varying the culture medium
(IMDM instead of RPMI), using culture medium with and
without antibiotics, or with BSA instead of human serum
(data not shown). The results were similar, showing that clone
S revealed specific lysis of recipient leukemic cells and of the
EBVLCL ofboth recipient and donor. Thus, clone S showed
HLA-DR2 restricted reactivity with leukemic cells from at
least two patients with AML (M5) and EBVLCLs. There-
fore, the antigen recognized appeared not to be an EBV
antigen.
Not only before, but also after BMT, CTL lines couldbe
generated, using the recipient peripheral blood MNC, col-
lected after BMT, as responder cells. These generated CTL
lines also showed the specific reactivity with the recipient
leukemic cells and not with the IL-2-stimulated T lympho-
cytes from the recipient. Therefore, these T cells may have
exhibited antileukemic reactivity afterBMT, and have attrib-
uted to the persistent remission.
In conclusion, we demonstrated that various MHC class
I and II-restricted leukemia-specific CTL clones can be gener-
ated in vitro from an HLA genotypically identical sibling
of a patient with AML. The donor-derived CTL clones with
reactivity with the recipient leukemic cells may explain GVL
reactivity after BMT In the treatment of leukemia, donor-
derived CTL clones that recognize the leukemic target cells
from the recipient and not the normal host cells of the tissues
that are involved in GVHD, may be used as adjuvant im-
munotherapeutic agents.
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